Sara Nordqvist Kleppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Sara Nordqvist Kleppe has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Camilla Lagheden
Center for Cervical Cancer Elimination, Karolinska Institutet, 171 77 Stockholm, Sweden
2 shared publications - Laila Sara Arroyo Mühr
International HPV Reference Center, Center for Cervical Cancer Elimination, F56, Karolinska Institutet, 141 86 Stockholm, Sweden
2 shared publications - Anna Månberg
Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
1 shared publication - August Jernbom Falk
KTH Royal Institute of Technology, SciLifeLab
1 shared publication - Carina Eklund
Karolinska Institutet
1 shared publication Cecilia Hellström
KTH Royal Institute of Technology, SciLifeLab
1 shared publication
Latest Publications
- Open Access
- 5 September 2025
- Published by Elsevier in Journal of Clinical Virology
- Vol. 181, 105869
Assessing sample adequacy and clinical performance of self-collected and clinician-collected HPV specimens using internal control Ct values
- 5 September 2025
- Published by Elsevier in Journal of Clinical Virology
- Vol. 181, 105869
Open AccessAssessing sample adequacy and clinical performance of self-collected and clinician-collected HPV specimens using internal control Ct values
- Open Access
Antibodies to SARS-CoV-2 and risk of future sickness
Background: The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. Method: We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: https:ClinicalTrials.gov NCT04411576 ). Results: Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)). Conclusion: Presence of viral antibodies marks past disease and protection against excess risk of future disease.
Open AccessAntibodies to SARS-CoV-2 and risk of future sickness
Background: The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. Method: We analyzed 12928 healthy hospital employees for SARS-CoV-2 antibodies and compared results to participant sick leave records (Clinical trial registration: https:ClinicalTrials.gov NCT04411576 ). Results: Subjects with viral serum antibodies were not at excess risk for future sick leave (Odds Ratio (OR): 0.85 (95% Confidence Interval (CI) (0.85 (0.43-1.68)). By contrast, subjects with antibodies had an excess risk for sick leave in the past weeks (OR: 3.34 (2.98-3.74)). Conclusion: Presence of viral antibodies marks past disease and protection against excess risk of future disease.